Effect of intraarticular injection of autologous adipose-derived mesenchymal stem and regenerative cells on clinical signs of chronic osteoarthritis of the elbow joint in dogs
Abstract
Autologous adipose-derived mesenchymal stem cell (AD-MSC) therapy involves harvesting fat from the patient, isolating the stem and regenerative cells, and administering the cells back to the patient. Autologous AD-MSC therapy in veterinary regenerative medicine has been commercially available since 2003. Previously reported results from a blinded, controlled trial in dogs with chronic osteoarthritis of the coxofemoral (hip) joint demonstrated efficacy of a single intraarticular injection of autologous AD-MSC therapy. The primary objective of the current study was to evaluate the effectiveness of this therapy in dogs with chronic osteoarthritis of the humeroradial (elbow) joints and to determine the duration of effect. Fourteen dogs were recruited. Veterinarians assessed each dog for lameness, pain on manipulation, range of motion, and functional disability using a numeric rating scale at baseline and specified intervals up to 180 days after treatment. Statistically significant improvement in outcome measures was demonstrated.
Chief Executive Officer at Gallant
Dr. Linda Black, DVM, PhD, is Chief Executive Officer of Gallant and a founding member of the company, previously serving as President and Chief Scientific Officer. She brings extensive leadership experience across biotechnology, spanning corporate development, research and development, operations, and commercialization, with deep expertise in regenerative medicine and stem cell therapies for pets.
Prior to Gallant, she served as President and Chief Scientific Officer of Medicus Biosciences and as Vice President of Product Development at VetStem Biopharma, where she helped pioneer the first off-the-shelf stem cell therapies for dogs. Dr. Black has authored foundational research on adipose-derived stem cells and has led programs advancing these therapies to commercialization. She holds a DVM from the University of Wisconsin–Madison and a PhD in Cell and Molecular Biology from the University of Pennsylvania.
